



PCSK9 Is Increased in Youth With Type 1 Diabetes

<https://doi.org/10.2337/dc16-2563>

Amy E. Levenson,¹ R. Paul Wadwa,²
Amy S. Shah,³ Philip R. Khoury,³
Thomas R. Kimball,⁴
Elaine M. Urbina,⁴
Sarah D. de Ferranti,⁵
Franziska K. Bishop,²
David M. Maahs,^{2,6}
Lawrence M. Dolan,³ and
Sudha B. Biddinger¹

Type 1 diabetes (T1D) is associated with a 10-fold increase in cardiovascular disease (CVD) risk, due in part to dyslipidemia. Patients with poorly controlled T1D show an increase in total and LDL cholesterol as well as elevated apolipoprotein B (ApoB) levels. Moreover, even patients with well-controlled T1D can show increased levels of ApoB. Dyslipidemia is particularly important in females with T1D, as the atheroprotective lipoprotein profile and reduced risk of CVD usually observed in females without diabetes are lost in females with diabetes (1,2).

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has recently emerged as a novel regulator of plasma cholesterol levels: gain-of-function PCSK9 mutations increase LDL cholesterol and CVD risk, whereas inhibitors of PCSK9 lower LDL cholesterol. Although PCSK9 is increased in individuals with obesity and type 2 diabetes (3,4), it is not known whether PCSK9 levels are also changed in individuals with T1D.

Here, we measured PCSK9 levels in a subset of a previously described cohort of T1D and control subjects (5). For the current study, subjects with serum available for PCSK9 measurement were matched for age and sex between each group using

the frequency matching method. Subjects who reported taking statin medications at the time of the study were excluded from the analyses ($n = 3$, all from T1D group). Variance-stabilizing measures to transform nonnormal values were performed as appropriate for parametric analyses. χ^2 analyses were performed to determine group differences for categorical variables. Independent t tests, one-way ANOVA, and ANCOVA were performed to test for mean differences between the groups. Correlations between PCSK9 and age, BMI, BMI z score, HbA_{1c}, systolic blood pressure, diastolic blood pressure, triglycerides, total cholesterol, LDL cholesterol, HDL cholesterol, and ApoB were assessed in each group by measuring the Spearman correlation coefficient; in this case, to account for multiple testing, $P < 0.002$ was considered significant.

Patients with T1D showed higher systolic and diastolic blood pressure measurements and ApoB levels, but normal total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol (Table 1). Serum PCSK9 concentrations were significantly higher in females and individuals with T1D. Thus, PCSK9 levels increased from 187 ± 67 ng/mL in control group males to 215 ± 83 ng/mL in control group

females, 253 ± 98 ng/mL in males with T1D, and 299 ± 106 ng/mL in females with T1D (Fig. 1) ($P < 0.002$ for the effects of sex; $P < 0.0001$ for the effects of T1D; and $P = 0.864$ for their interaction). In the control group, PCSK9 was significantly correlated with total cholesterol ($r_s = 0.51$) and ApoB ($r_s = 0.40$). In the T1D group, PCSK9 was significantly correlated with HbA_{1c} ($r_s = 0.36$), triglycerides ($r_s = 0.24$), total cholesterol ($r_s = 0.39$), LDL cholesterol ($r_s = 0.31$), and ApoB ($r_s = 0.31$).

Three findings from this study should be noted. First, PCSK9 levels are higher in subjects with T1D than in control subjects without diabetes. The liver is the major source of serum PCSK9 (6), and insulin increases PCSK9 expression and secretion in hepatocytes (7). Consequently, plasma PCSK9 levels in adults with T1D are positively correlated with insulin dose (8). Conversely, mice with livers unable to respond to insulin because of a deletion of the hepatic insulin receptor show a marked decrease in plasma PCSK9 (9). Because individuals with T1D are relatively deficient in hepatic insulin signaling owing to the lack of endogenous insulin stimulation from the portal circulation, their increased levels of serum PCSK9 were

¹Division of Endocrinology, Boston Children's Hospital, Harvard Medical School, Boston, MA

²Barbara Davis Center for Childhood Diabetes, University of Colorado School of Medicine, Aurora, CO

³Division of Endocrinology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH

⁴Division of Cardiology, Cincinnati Children's Hospital Medical Center and University of Cincinnati, Cincinnati, OH

⁵Department of Cardiology, Boston Children's Hospital, Harvard Medical School, Boston, MA

⁶Division of Endocrinology and Diabetes, Department of Pediatrics, Stanford University School of Medicine, Stanford, CA

Corresponding author: Sudha B. Biddinger, sudha.biddinger@childrens.harvard.edu.

Received 30 November 2016 and accepted 11 April 2017.

© 2017 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at <http://www.diabetesjournals.org/content/license>.

Table 1—Demographic and clinical characteristics of T1D case subjects and control subjects in the study population

Patient characteristics	Control (n = 74)	T1D (n = 176)	P value*
Age (years)	15.4 (2.2)	15.2 (2.2)	0.64
Duration of diabetes (years)	—	8.6 (2.9)	
Sex, female, n (%)	42 (57)	99 (56)	0.92
Race, %			0.03
Non-Hispanic white	68	83	
African American	11	3	
Hispanic	11	6	
Other	10	9	
Tanner stage, %‡			0.77
1	5	4	
2	13	10	
3	16	12	
4	24	25	
5	42	49	
BMI (kg/m ²)	21.8 (4.2)	22.4 (3.4)	0.03
BMI z score	0.27 (1.0)	0.55 (0.77)	0.04
HbA _{1c} (%; mmol/mol)	5.3 (0.3), 34 (2.9)	9.0 (1.6), 75 (17.5)	<0.001
Systolic BP (mmHg)	109 (8)	113 (9)	<0.001
Diastolic BP (mmHg)	64 (6)	69 (6)	<0.001
Total cholesterol (mg/dL)	148 (28)	159 (35)	0.47
LDL cholesterol (mg/dL)	82 (23)	90 (28)	0.39
HDL cholesterol (mg/dL)	49 (9)	52 (11)	0.29
Triglycerides (mg/dL)	83 (42)	87 (50)	0.33
ApoB (mg/dL)	69 (19)	77 (23)	0.003
PCSK9 (ng/mL)	203 (77)	279 (104)	0.0001

Values are mean (SD), unless otherwise indicated. BP, blood pressure. *Comparisons between groups determined using *t* tests if variables were normally distributed or normality was achieved with log transformation. Boldface type indicates statistical significance where *P* < 0.05. ‡Tanner stage refers to pubic hair development by provider report.

somewhat surprising and suggest that factors other than insulin may also play an important role in the regulation of PCSK9. Second, among subjects with T1D, PCSK9 levels are correlated with HbA_{1c}. Similar positive associations between

PCSK9 and HbA_{1c} have been observed in other T1D cohorts (8), and this result is consistent with the greater degree of dyslipidemia found in T1D patients with poor glycemic control. Finally, PCSK9 levels are higher among females, in both the




Figure 1—Comparison of PCSK9 levels by sex within each group. Data are mean and SD. Two-way ANOVA comparison results are also shown. #*P* < 0.0001, subjects with T1D vs. control subjects. **P* < 0.002, females vs. males.

control and T1D groups, consistent with prior studies of PCSK9 in other populations (3). It has been suggested that sex steroids may be responsible for the increase in PCSK9 observed in females (10). However, we compared PCSK9 levels in the female subjects who were Tanner stages 1–3 (prepubertal or early puberty, with presumed low sex steroid levels) versus Tanner stage 5 (postpuberty, or presumed high sex steroid levels) and found that neither the Tanner stage nor the interaction between Tanner stage and diabetes was significant.

In summary, our results in a youth cohort indicate that PCSK9 levels are higher in females compared with males, higher in subjects with T1D than in control subjects, and correlated with HbA_{1c}. Future work will be necessary to understand the contribution of PCSK9 to the dyslipidemia and increased CVD risk associated with T1D, particularly in females.

Funding. This study was supported by the National Institutes of Health (NIH) National Institute of Diabetes and Digestive and Kidney Diseases grant 5K12-DK-094721-04 (A.E.L.) and NIH National Heart, Lung, and Blood Institute grant R01-HL-109650 (S.B.B.). This research was also funded by JDRF (11-2007-694), NIH/National Center for Research Resources Colorado Clinical Translation and Science Institute (UL1-RR-025780), the Children's Hospital Colorado Pediatric Clinical and Translational Research Center (M01-RR-00069), and the Diabetes Endocrinology Research Centers Core (P30-DK-57516). Its contents are the authors' sole responsibility and do not necessarily represent official NIH views.

Duality of Interest. No conflicts of interest relevant to this study were reported.

Author Contributions. A.E.L., R.P.W., F.K.B., D.M.M., and S.B.B. designed the study. A.E.L. performed the PCSK9 assays and analyzed the data. F.K.B. facilitated sample and data transfer. P.R.K. conducted the statistical analysis. A.E.L. and S.B.B. wrote the manuscript. R.P.W., A.S.S., T.R.K., E.M.U., S.D.d.F., D.M.M., and L.M.D. reviewed and edited the manuscript. S.B.B. is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and accuracy of the data analysis.

References

- Walden CE, Knopp RH, Wahl PW, Beach KW, Strandness E Jr. Sex differences in the effect of diabetes mellitus on lipoprotein triglyceride and cholesterol concentrations. *N Engl J Med* 1984; 311:953–959
- Maahs DM, Hokanson JE, Wang H, et al. Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance. *Diabetes* 2010;59:1771–1779

3. Lakoski SG, Lagace TA, Cohen JC, Horton JD, Hobbs HH. Genetic and metabolic determinants of plasma PCSK9 levels. *J Clin Endocrinol Metab* 2009;94:2537–2543
4. Levenson AE, Shah AS, Khoury PR, et al. Obesity and type 2 diabetes are associated with elevated PCSK9 levels in young women. *Pediatr Diabetes*. 17 January 2017 [Epub ahead of print]. DOI: 10.1111/pedi.12490
5. Brown TL, Maahs DM, Bishop FK, Snell-Bergeon JK, Wadwa RP. Influences of gender on cardiovascular disease risk factors in adolescents with and without type 1 diabetes. *Int J Pediatr Endocrinol* 2016;2016:8
6. Zaid A, Roubtsova A, Essalmani R, et al. Proprotein convertase subtilisin/kexin type 9 (PCSK9): hepatocyte-specific low-density lipoprotein receptor degradation and critical role in mouse liver regeneration. *Hepatology* 2008;48:646–654
7. Costet P, Cariou B, Lambert G, et al. Hepatic PCSK9 expression is regulated by nutritional status via insulin and sterol regulatory element-binding protein 1c. *J Biol Chem* 2006;281:6211–6218
8. Laugier-Robiolle S, Vergès B, Le Bras M, et al. Glycaemic control influences the relationship between plasma PCSK9 and LDL cholesterol in type 1 diabetes. *Diabetes Obes Metab* 2017;19:448–451
9. Miao J, Manthena PV, Haas ME, et al. Role of insulin in the regulation of proprotein convertase subtilisin/kexin type 9. *Arterioscler Thromb Vasc Biol* 2015;35:1589–1596
10. Ghosh M, Gälman C, Rudling M, Angelin B. Influence of physiological changes in endogenous estrogen on circulating PCSK9 and LDL cholesterol. *J Lipid Res* 2015;56:463–469